Chief Operating Officer
Hugh Yu, Ph.D.
- Experienced CMC expert with 16 years of demonstrated scientific strength and leadership of academic, startup biotech, contract research and commercial manufacturing.
- Ad Hoc Journal Reviewer for Scientific Reports (nature portfolio).
- A total of more than 21 international journal papers, seminar papers, and reports have been published. Applied for 26 international invention patents.
- Over 11 years of work experience following graduate work (Pharma/biotech) and management experience in leading and line management of research teams on a day-to-day basis, with the added distinction of successfully completing of the Stanford LEAD Program.
- Completed the pre-IND meeting package, Orphan-Drug Designation (ODD) submission application, multiple Investigational New Drug (IND) clinical submission applications, and Biologics License Application/New Drug Application (BLA/NDA) submission for the United States and China.
- Involved in various biomedical projects, including the development of recombinant anti-tumor proteins, oncolytic viruses, monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADC), AAV-derived gene therapy, iPSC-derived cell therapy (CAR-NK), and antimicrobial peptides (AMPs), immune system protein and aptamer molecule and other biosimilar product research and development projects.
